Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled TrialReportar como inadecuado


Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial


Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1

Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

2

Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

3

Graduate Institute of Natural Product, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan

4

Department of Family Medicine, Pingtung Hospital, Ministry of Health and Welfare, Pingtung 928, Taiwan

5

Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

6

Center for Biomarkers and Biotech Drugs, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

7

Research Center for Environmental Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

8

Research Center for Natural Products and Drug Development, Kaohsiung Medical University, Kaohsiung 807, Taiwan



Presented at the Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology, San Francisco, CA, USA, 19–21 January 2017.



The authors have contributed equally to this work.





*

Author to whom correspondence should be addressed.



Academic Editor: Vassilios Roussis

Abstract Background: Low-molecular-weight fucoidan LMF is widely used as a food supplement for cancer patients. However, all of the studies are in vitro or were conducted using mice. Therefore, powerful clinical evidence for LMF use is relatively weak. This study aimed to evaluate the efficacy of LMF as a supplemental therapy to chemo-target agents in metastatic colorectal cancer mCRC patients. Methods: We conducted a prospective, randomized, double-blind, controlled trial to evaluate the efficacy of LMF as a supplemental therapy to chemotarget agents in patients with metastatic colorectal cancer mCRC. Sixty eligible patients with mCRC were included. Finally, 54 patients were enrolled, of whom 28 were included in the study group and 26 in the control group. The primary endpoint was the disease control rate DCR, and secondary endpoints included the overall response rate ORR, progression-free survival PFS, overall survival OS, adverse effects AEs, and quality of life QOL. Results: The DCRs were 92.8% and 69.2% in the study and control groups, respectively p = 0.026, in a median follow-up period of 11.5 months. The OS, PFS, ORR, AEs, and QOL did not significantly differ between the two groups. Conclusion: This is the first clinical trial evaluating the efficacy of LMF as a supplemental therapy in the management of patients with mCRC. The results indicate that LMF combined with chemotarget agents significantly improved the DCR. View Full-Text

Keywords: low-molecular-weight fucoidan; metastatic colorectal cancer; supplemental therapy; disease control rate low-molecular-weight fucoidan; metastatic colorectal cancer; supplemental therapy; disease control rate





Autor: Hsiang-Lin Tsai 1,2,‡, Chi-Jung Tai 3,4,‡, Ching-Wen Huang 1,2, Fang-Rong Chang 3 and Jaw-Yuan Wang 1,2,5,6,7,8,†,*

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados